Cohort baseline characteristics
| Demographics | N (%) |
|---|---|
| Female sex | 4345 (39.6%) |
| Age (mean) | 59.3 |
| Median household income in zip | |
| <$50 000 | 3719 (33.8%) |
| $50 000–$99 999 | 6457 (58.6%) |
| $100 000+ | 834 (7.6%) |
| Per cent black in zip, mean (SD) | 12.3 (17.9%) |
| Per cent ≥HS education, mean (SD) | 86.9 (8.5%) |
| Region | |
| Midwest | 2122 (19.3%) |
| Northeast | 3053 (27.7%) |
| South | 4750 (43.1%) |
| West | 1085 (9.9%) |
| Index statin (generic) | |
| Amlodipine/atorvastatin | 56 (0.5%) |
| Atorvastatin | 2474 (22.5%) |
| Fluvastatin | 23 (0.2%) |
| Lovastatin | 436 (4.0%) |
| Niacin/lovastatin | 17 (0.2%) |
| Niacin/simvastatin | 69 (0.6%) |
| Pitavastatin | 96 (0.9%) |
| Pravastatin | 1441 (13.1%) |
| Rosuvastatin | 1760 (16.0%) |
| Simvastatin | 4638 (42.1%) |
| Copayment index statin prescription, mean (SD) | $24.70 ($26.10) |
| Comorbidity medications | N (%) |
| Coronary artery disease | 391 (3.6%) |
| Asthma/COPD | 1172 (10.6%) |
| Diabetes | 2219 (20.2%) |
| Congestive heart failure | 246 (2.2%) |
| Hypertension | 6105 (55.4%) |
| Mental health and depression | 2074 (18.8%) |
| Platelet inhibitor | 603 (5.5%) |
| Loop diuretic | 545 (5.0%) |
| Antiarrhythmics | 122 (1.1%) |
| Osteoporosis | 481 (4.4%) |
| Anticoagulant | 383 (3.5%) |
| Total number of medications, mean (SD) | 5.3 (4.2) |
COPD, chronic obstructive pulmonary disease; HS, higher secondary.